488 related articles for article (PubMed ID: 17110824)
21. Validation of the adult ADHD investigator symptom rating scale (AISRS).
Spencer TJ; Adler LA; Meihua Qiao ; Saylor KE; Brown TE; Holdnack JA; Schuh KJ; Trzepacz PT; Kelsey DK
J Atten Disord; 2010 Jul; 14(1):57-68. PubMed ID: 19794135
[TBL] [Abstract][Full Text] [Related]
22. The reliability and validity of self- and investigator ratings of ADHD in adults.
Adler LA; Faraone SV; Spencer TJ; Michelson D; Reimherr FW; Glatt SJ; Marchant BK; Biederman J
J Atten Disord; 2008 May; 11(6):711-9. PubMed ID: 18025250
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.
Escobar R; Schacht A; Wehmeier PM; Wagner T
J Clin Psychopharmacol; 2010 Apr; 30(2):145-51. PubMed ID: 20520287
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
28. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
[TBL] [Abstract][Full Text] [Related]
31. Atomoxetine for attention deficit/hyperactivity disorder.
Garces K
Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
[TBL] [Abstract][Full Text] [Related]
32. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.
Sobanski E; Sabljic D; Alm B; Baehr C; Dittmann RW; Skopp G; Strohbeck-Kuehner P
Pharmacopsychiatry; 2012 May; 45(3):100-7. PubMed ID: 22174029
[TBL] [Abstract][Full Text] [Related]
33. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
[TBL] [Abstract][Full Text] [Related]
34. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
[TBL] [Abstract][Full Text] [Related]
35. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder.
Weiss MD; Gibbins C; Goodman DW; Hodgkins PS; Landgraf JM; Faraone SV
J Clin Psychiatry; 2010 Apr; 71(4):381-90. PubMed ID: 20361900
[TBL] [Abstract][Full Text] [Related]
36. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
37. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
38. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
Young JL; Sarkis E; Qiao M; Wietecha L
Clin Neuropharmacol; 2011; 34(2):51-60. PubMed ID: 21406998
[TBL] [Abstract][Full Text] [Related]
39. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
Faraone SV; Wigal SB; Hodgkins P
J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
[TBL] [Abstract][Full Text] [Related]
40. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Barton J
Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]